Vibe Bio

How Orphan Therapeutics Accelerator Is Optimizing Rare Disease Search & Eval How Orphan Therapeutics Accelerator uses Vibe Bio for rare disease due diligence, pipeline & competitive analysis, & in-licensing strategy.

Rare disease teams face too much noise and not enough clarity. The Orphan Therapeutics Accelerator helps biotechs identify promising rare disease programs with speed + rigor.

Our new case study shows how Vibe Bio’s AI platform made that possible.

vibebio.com/blog/orphan-...
#AI #raredisease #otxl

How Incite partnered with Vibe Bio to accelerate the search & evaluation of sarcoma drugs Learn how Vibe Bio helped Incite accelerate sarcoma drug discovery with unbiased ranking and AI-powered compound analysis.

NGL, super excited to share our first case study!

Speed matters in rare disease drug discovery. Incite and Vibe Bio partnered to filter dozens of assets into a focused, high-potential set to pursue — fast and defensible.

Read more here:

vibebio.com/blog/incite-...

Why BD teams cannot afford to lose their memory & how AI can help Even with databases, access to prior knowledge in biotech BD teams often breaks down. The antidote is simple : build durable organizational memory. AI can help.

In biotech BD, lost context means lost opportunity. AI can help capture every decision, touchpoint, and rationale so your team never has to start from scratch again.

Read more:
vibebio.com/blog/why-bd-...

#Biotech #AI #Strategy

Alok Tayi, PhD & CEO+cofounder @ Vibe Bio, will be on a panel discussion about AI in healthcare at the STS Forum 2025 in Kyoto next week.

Date & Time
October 6, 2025 (Monday) 10:40-12:40 120 min.
Session Room B-1.

🔗 www.stsforum.org/kyoto2025/de...
#AI #biotech #STSForum

Targeting MHC-E as a new strategy for vaccines and immunotherapeutics | Nature Reviews Immunology MHC-E is a highly conserved, non-polymorphic MHC protein that engages inhibitory and activating receptors on natural killer (NK) cells and T cells and can also present antigens to T cell receptors. NK cell responses driven by activating receptor interactions with MHC-E are implicated in controlling chronic viral infections and cancer. Immunotherapeutic targeting of interactions between MHC-E and inhibitory receptors to increase the activation of NK cells and T cells shows promise in improving antitumour immune responses. Furthermore, MHC-E-restricted CD8+ T cells elicited by cytomegalovirus-based vaccines might, for certain infections and cancers, be more effective than CD8+ T cells restricted by classical MHC class I or class II molecules. The ability of MHC-E to regulate or mediate both innate and adaptive immune responses independently of the MHC haplotype of an individual raises the possibility of new, universally effective vaccines and immunotherapies for infectious disease and ca

Targeting MHC-E to boost NK & T cell activation may enhance vaccines and cancer therapies, tackling chronic infections. PMID:40903525, Nat Rev Immunol 2025, @NatRevImmunol https://doi.org/10.1038/s41577-025-01218-6 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪

Vibe Bio Newsletter — September 2025 Welcome to the Vibe Bio newsletter — your monthly window into the breakthroughs, bold ideas, and collective progress driving our mission: every cure for every community.

Check out our latest post, with insights about biopharma, artificial intelligence, and some travel pics from the team.

open.substack.com/pub/vibebio/...
#biopharma #AI #cats_of_world

Molecular basis of ligand binding and receptor activation at the human A3 adenosine receptor | Nature Communications Adenosine receptors (ARs: A1AR, A2AAR, A2BAR, and A3AR) are crucial therapeutic targets; however, developing selective, efficacious drugs for them remains a significant challenge. Here, we present high-resolution cryo-electron microscopy (cryo-EM) structures of the human A3AR in three distinct functional states: bound to the endogenous agonist adenosine, the clinically relevant agonist Piclidenoson, and the covalent antagonist LUF7602. These structures, complemented by mutagenesis and pharmacological studies, reveal an A3AR activation mechanism that involves an extensive hydrogen bond network from the extracellular surface down to the orthosteric binding site. In addition, we identify a cryptic pocket that accommodates the N6-iodobenzyl group of Piclidenoson through a ligand-dependent conformational change of M1745.35. Our comprehensive structural and functional characterisation of A3AR advances our understanding of adenosine receptor pharmacology and establishes a foundation for devel

Explore the human A3 adenosine receptor through 3 distinct cryo-EM structures: endogenous agonist adenosine, agonist Piclidenoson, and antagonist LUF7602! PMID:40825947, Nat Commun 2025, @NatureComms https://doi.org/10.1038/s41467-025-62872-x #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪

Webinar: The AI buyer's guide for BD&L executives. Learn how to evaluate and choose AI solutions to achieve real results in biopharma

📅 Today's the day! Register now to join us at 1 PM ET to get a practical, executive-level framework to evaluate AI solutions for BD&L teams. You’ll learn:
📷 Which features matter most
📷 A framework to evaluate vendors
📷 #biopharma
hubs.ly/Q03HbtX-0
#AI #bizdev

Join us for an educational session on September 24 at 1 PM ET. We'll walk through an executive-level framework for evaluating AI solutions for BD&L teams.
You’ll learn:
> AI adoption & risks
> Build, buy, or partner options
> Types/tradeoffs of existing solutions
vibebio.com/resources/ev...

The AI buying guide for BD&L executives This webinar offers an AI buying guide for BD&L executives, including a framework for evaluating and choosing the right AI solutions to achieve results.

Not all AI is created equal.

For BD teams in biopharma, the right platform can transform how you evaluate assets & partners.

🎥 Join our webinar on September 24 @ 1 PM ET for The AI Buying Guide for BD Executives
👉 vibebio.com/resources/ev...
#businessdevelopment #AI #biopharma

From overwhelm to clarity: prioritizing assets with AI-powered confidence Facing a flood of biopharma assets? Learn how AI can help your BD team cut through the noise, gain confidence, and act with purpose.

Portfolio strategy is where biopharma wins or loses.
Yet too many teams still rely on gut feel and incomplete data.

AI changes the equation—bringing speed, context, and clarity to asset prioritization.

We break it down here:
vibebio.com/blog/priorit...
#Biopharma #AI #PortfolioStrategy

Modern biopharma BD: How to find the diamonds in the rough Discover how top biopharma BD teams find diamonds in the rough by prioritizing strategic clarity, disciplined pipeline triage, and asset tracking.

The bottleneck in BD isn’t access to assets—it’s clarity.

Too many decks. Too little time.
And the loudest signals aren’t always the best ones.

New blog on what a better diligence model could look like:
🔗 vibebio.com/blog/modern-...

Home An AI software company with a venture capital arm, our mission at Vibe Bio is to find every cure for every community. We help biopharmas make strategic drug pipeline decisions with greater speed and a...

Great discussions at #BIO2025 about AI & BD strategy.
A few takeaways from our conversations at the event:
📈 BD teams want better decision support
⚡️ Speed to insight matters
🎯 The intersection of AI + human expertise is where the real edge is
Learn more vibebio.com

Navigating Pharma Strategy and Portfolio Prioritization: A Q&A The ability to make disciplined, well-informed decisions around portfolio strategy and asset prioritization in biopharma is more important than ever

Portfolio strategy in pharma isn’t just art—or science. It’s both.
Read this post to learn:
🎯 Why better prioritization matters now more than ever
🧠 The hidden cost of legacy decision-making
⚡ How AI changes the game

👉 vibebio.com/blog/navigat...
#Biotech #Pharma #AI

Home An AI software company with a venture capital arm, our mission at Vibe Bio is to find every cure for every community. We help biopharmas make strategic drug pipeline decisions with greater speed and a...

#BIO2025 — Lots of great convos about drug development.

Key themes we are hearing:
📊 BD teams need better precision & faster turnaround
🧠 Human expertise + AI is a winning combo
🗺️ AI can help explore adjacencies & new opportunities
Want to learn more?
Visit 👉 vibebio.com
#biopharma #ai

Webinar: Surrogate Outcomes in Health Technology Assessment - Accelerating Access to Breakthrough Treatments Surrogate outcomes play an important role in modern healthcare research. Join us for this webinar where our experts will focus on methods and guidelines for establishing surrogate outcomes and how the...

Next week on June 18, our experts will be hosting a webinar where they discuss methods and guidelines for establishing surrogate outcomes. Learn how they have been used in health technology assessments to date. Register today! ow.ly/BA9r50VOqLt 🧪 PharmSky Medsky HTA

Unveiling the structural spectrum of SARS-CoV-2 fusion by in situ cryo-ET | Nature Communications SARS-CoV-2 entry into host cells is mediated by the spike protein, which drives membrane fusion. While cryo-EM reveals stable prefusion and postfusion conformations of the spike, the transient fusion intermediate states during the fusion process remain poorly understood. Here, we design a near-native viral fusion system that recapitulates SARS-CoV-2 entry and use cryo-electron tomography (cryo-ET) to capture fusion intermediates leading to complete fusion. The spike protein undergoes extensive structural rearrangements, progressing through extended, partially folded, and fully folded intermediates prior to fusion-pore formation, a process that depends on protease cleavage and is inhibited by the WS6 S2 antibody. Upon interaction with ACE2 receptor dimer, spikes cluster at membrane interfaces and following S2’ cleavage concurrently transition to postfusion conformations encircling the hemifusion and initial fusion pores in a distinct conical arrangement. S2’ cleavage is indispensable fo

SARS-CoV-2 entry captured: Cryo-ET reveals fusion intermediates of spike protein during membrane fusion, bridging stable pre- and postfusion states. PMID:40461447, Nat Commun 2025, @NatureComms https://doi.org/10.1038/s41467-025-60406-z #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪

Long-COVID diagnoses fairly common in Medicare claims Beneficiaries with 4 or more COVID-19 vaccine doses had a 39% lower rate of long COVID.

www.cidrap.umn.edu/covid-19/lon...
#MedSky #pharmsky

New AJDAA Article Regulation of HDL metabolism in alcohol-associated liver disease: the role of HIF-1α and miR-185 in SR-BI suppression

New study reveals how #alcohol use can upregulate transcription factor and microRNA processes. This can disrupt metabolic processes associated with alcohol-associated #liver disease. Targeting this pathway could open doors to new ALD treatments. www.tandfonline.com/doi/full/10....

Microbiome–metabolome dynamics associated with impaired glucose control and responses to lifestyle changes - Nature Medicine A map of microbiome–metabolome dynamics in people with type 2 diabetes identifies over 500 blood metabolites associated with impaired glucose control, with approximately one-third linked to an altered...

Microbiome–metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. #NatureMedicine

"Short-term lifestyle changes, for example, diet and exercise, modulated microbiome-associated metabolites in a lifestyle-specific manner."

www.nature.com/articles/s41...

Bottlenecks to breakthroughs: How AI is reshaping biopharma BD&L Webinar: May 28, 1 PM ET (Available on demand shortly thereafter)

⏳ In ~30 minutes: join our live webinar on how #AI is streamlining #biopharma #businessdevelopment.
Learn:
– Best practices from top BD teams
– Industry shifts driving demand for in-licensing
– How AI helps prioritize, benchmark, and diligence assets at scale
Tune in:
vibebio.com/resources/ev...

Women's health | Chemistry World Many medical conditions affect only women, or affect them disproportionately, but women's health has historically been neglected in medical research. In this collection, we look at the gender gap in h...

It's the International Day of Action for Women's Health. Our latest collection explores how women’s health has historically been neglected in medical research, looking at the gender gap in health and drugs, the safety of period products, changing menopause treatments and more. #WomensHealthMatters

A new dawn for psychedelics? Compass could be the first to find out Compass awaits Phase 3 COMP360 trial results for treatment-resistant depression amid renewed optimism for psychedelics.

At the risk of sounding too horse race-y, Lykos' pain last year was Compass' gain in the race for the first FDA approved #psychedelic. My colleague Ayisha Sharma has a deeply reported story on the new frontrunner, and how commercial preparations are already underway.

endpts.com/a-new-dawn-f...

This year's theme for International Clinical Trials Day is "Rethinking Clinical Trials: Inclusivity in Practice."

@biorasi.bsky.social recognizes the dedication of our colleagues in the #clinicaltrial industry, and we look forward to new ways to optimize diversity in global studies.

Somite AI Raises $47M Series A To Reinvent Cell Replacement Therapy With its AI foundation model and platform, Somite AI aims to overcome the key challenges of current lab-based stem cell development.

Great news for Somite AI, whose "foundation models, once fully developed and validated, will not only create value for their own pipeline, but have the potential to reshape the entire field of human cell therapy,” according to legendary investor Vinod Khosla. #AI #fund www.forbes.com/sites/gilpre...

Early bits of in vivo CAR-T human data emerge from biotech trials in China Initial clinical data from Genocury and EsoBiotec shows promise for in vivo CAR-T therapy, with complete remission in lymphoma and myeloma patients without lymphodepletion.

Two in vivo CAR-T trials in China have delivered early human data, the first clinical readouts of a competitive field.
endpts.com/early-in-viv...

The Science of Drug Development: Lessons from a Pioneer in Pharmaceutical Decision-Making Jay Andersen, a pioneer in pharmaceutical decision-making, shared lessons developing portfolio management & probability assessment methods.

Insights from pharma pioneer Jay Andersen on portfolio management & probability assessment. This is a must-read for industry leaders interested in the three critical success factors in portfolio management:
vibebio.com/blog/lessons...
#Pharma #DecisionMaking #DrugDevelopment

Orphan Therapeutics Accelerator Announces Foundational Partnerships The Orphan Therapeutics Accelerator (OTXL), a non-profit biotech organization focused on completing development and commercializing therapies for ultra-rare ...

The Orphan Therapeutics Accelerator is up and running! The goal of this #nonprofit is to in-license stalled #rarediseasedrugs, advance them, then move them to #pharma to commercialize. Proceeds will enable us develop #rarediseasetherapeutics and help more people.
www.businesswire.com/news/home/20...

Biopharma BD&L: the tsunami is upon us Pharma’s business development and licensing (BD&L) teams are navigating a complex marketplace and traditional approaches aren't working.

As the #biopharma industry navigates an increasingly complex marketplace, traditional approaches to identifying & evaluating potential #drugcandidates are straining.
What led to this tsunami of pressure and how can BD&L teams weather these challenges?
Learn more in this post:
bit.ly/4lFhcch #bdandl

Thank you, @shematologist.medsky.social for sharing this. 🩷

I hemorrhaged during childbirth, bruised easily my whole life, & had multiple other symptoms. I am SO thankful for a doctor who finally listened & diagnosed me. It has not only helped me, but has led to my children being diagnosed as well.